growth factor antagonist therapy
growth factor antagonist therapy is a medical procedure with 7 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
5
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
14.3%
1 of 7 finished
85.7%
6 ended early
0
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Gene Therapy in Treating Patients With Advanced Head and Neck Cancer
Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer
Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors
S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix
Clinical Trials (7)
Gene Therapy in Treating Patients With Advanced Head and Neck Cancer
Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer
Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors
S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
Celecoxib in Preventing Skin Cancer
All 7 trials loaded
Drug Details
- Intervention Type
- PROCEDURE
- Total Trials
- 7